New Pharmax HLC Baby Probiotic Supplements are Safe and Effective in Supporting Skin Health

Pittsburgh, PA, March 24, 2015 Pharmax, a trusted Seroyal brand and a North American leader in probiotics offering a comprehensive line of professional-grade, evidence-based nutraceuticals, is proud to announce its new HLC Baby B and HLC Baby F probiotic supplements. In a recent clinical trial, the HLC Baby probiotic formulas were found to be safe and effective in reducing incidence of skin sensitivity in infants.* HLC Baby B is designed for breast-fed babies, and HLC Baby F is ideal for formula-fed babies.

The probiotic strains used in the HLC Baby B and HLC Baby F probiotic formulas were evaluated in a recent clinical trial. Key findings from the 2014 placebo-controlled clinical trial conducted by Allen et al. showed that probiotic supplementation with the HLC Baby B and F strains in babies from birth to 6 months reduced skin prick reaction by 44 percent and reduced skin sensitivity by 57 percent.

Additionally, a 2010 safety study conducted by Allen et al., found that the usage of these probiotic strains did not increase adverse event incidence, number of visits to the doctor, or mothers’ assessment of infant health. Based on these findings, the authors concluded that usage of the probiotic formula was safe during early infancy.

“A healthy gut flora plays an important role in early immune stimulation, and variations in gut colonization at early ages have been associated with the development of atopy,” said Dr. Nigel Plummer, key research contributor at Pharmax. “Our new HLC Baby probiotic supplements support early colonization of bacteria in an infant’s gut to reduce incidence of skin sensitivity.”

Intestinal colonization of probiotics such as Lactobacillus and Bifidobacterium helps to promote optimal immune function and skin health in young children.* HLC Baby B and HLC Baby F both provide Lactobacillus and Bifidobacterium – two of the most common categories of probiotic bacteria that tend to be lower in infants with skin sensitivity. According to the American Academy of Dermatologists, skin sensitivity affects between 10 and 20 percent of all infants, making it the most common skin issue in children.

HLC probiotics are proprietary human-sourced microflora bacterial strains that exhibit strong epithelial adherence and a naturally high tolerance to stomach acid. The HLC Baby supplements are available in a powder format that dissolves easily into breast milk, formula or water and are free of gluten and soy.

For more information about Pharmax or the HLC Baby products, please visit www.seroyal.com/brands/pharmax.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

References:

Allen 2014

Stephen J. Allen, Sue Jordan, Melanie Storey, Catherine A. Thornton, Michael B. Gravenor, Iveta Garaiova, Susan F. Plummer, Duolao Wang, Gareth Morgan. Arch. Dis. Child. 2014; 99: 11 1014-1019

Allen 2010

Stephen J. Allen, Susan Jordan, Melanie Storey, Catherine A. Thornton, Michael Gravenor,

Iveta Garaiova, Susan F. Plummer, Duolao Wang, and Gareth Morgan. Dietary supplementation with Lactobacilli and Bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J. Nutri. 2010; 483-488

ABOUT PHARMAX

Pharmax, a trusted brand of Seroyal, a business unit of Atrium Innovations Inc. is a leading-edge, comprehensive line of professional grade nutraceuticals products built upon a 15 year research-driven, evidence-based scientific foundation. Pharmax is continuously looking at improving or adding efficacious products to the range of nutritional products available to the healthcare practitioner. Pharmax is headquartered in Richmond Hill, ON, Canada. For additional information, please visit www.seroyal.com/pharmax

ABOUT ATRIUM INNOVATIONS

Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products which are distributed in more than 35 countries.  The Company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education.  Atrium has over 1,500 employees and operates seven manufacturing facilities complying with current Good Manufacturing Practices. Additional information is available at www.atrium-innovations.com.

MEDIA CONTACT:
Gabriella Gasparich
Chemistry Communications
p: 412-224-6070
e: gabriella@createareaction.com

Recent Posts